Tumor Lysis Syndrome in Lymphoblastic Crisis of CML.
10.5045/kjh.2006.41.2.119
- Author:
Duk Joo LEE
1
;
Chi Un CHOI
;
Chung Sik LEE
;
Hak Hyun LEE
;
Jin Kyu PARK
;
Jung Hye CHOI
;
Young Yeul LEE
;
In Soon KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. kimis@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Tumor lysis syndrome;
Chronic myelogeous leukemia;
Blast crisis
- MeSH:
Acute Kidney Injury;
Blast Crisis;
Breast Neoplasms;
Burkitt Lymphoma;
Drug Therapy;
Extracellular Space;
Female;
Humans;
Hyperkalemia;
Hyperphosphatemia;
Hyperuricemia;
Hypocalcemia;
Incidence;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Small Cell Lung Carcinoma;
Testicular Neoplasms;
Tumor Lysis Syndrome*;
Uremia
- From:Korean Journal of Hematology
2006;41(2):119-123
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tumor lysis syndrome (TLS) defines the metabolic derangements that occur with tumor breakdown following the initiation of cytotoxic therapy. TLS results from the rapid destruction of malignant cells and the abrupt release of intracellular materials and their metabolites into the extracellular space. The syndrome causes hyperuricemia, hyperkalemia, hyperphosphatemia, secondary hypocalcemia and uremia. It can result in acute renal failure and be fatal. Early recognition of patient at risk and preventive measures are important. There is a high incidence of TLS in tumors with high proliferative rates and large burden such as acute lymphoblastic leukemia and Burkitt's lymphoma. It less commonly occurs in solid tumors such as testicular cancer, breast cancer and small cell lung cancer. There are only a few reports on TLS complicated in CML in blast crisis. So we report a 45-yr-old woman presenting with TLS associated with CML in lymphoblastic crisis after the initiation of cytotoxic chemotherapy.
